tbuckley/cabot-search huggingface dataset:
Republican health reform bill would increase uninsured by 24 million in a decade, report finds
Authors: Michael McCarthy
Journal: BMJ (2017)

Should the current Republican bill to replace the Affordable Care Act become law this year, 24 million more American people will be without health insurance by 2026 than would have been if the Affordable Care Act remained in place, an analysis has found.

The conclusion of the independent US Congressional Budget Office (CBO)1 is likely to stiffen opposition to the Republican bill, called the American Health Care Act. The act has already drawn criticism from most major US health organizations, including the American Medical Association and the American Hospital Association, and faces fierce opposition from Democrats.

“These are remarkable figures,” Nancy Pelosi, democratic leader of the House of Representatives, said after the …
Fixed dose rate (FDR) gemcitabine (G) and capecitabine (C) in patients with metastatic biliary tract cancer (BTC): Final results of phase II trial
Authors: D. Santini, B. Vincenzi, E. Vasile, V. Catalano, V. Virzì, G. Masi, S. Intagliata, G. Catalano, A. Falcone, G. Tonini
Journal: Journal of Clinical Oncology (2009)

e15510 Background: The combination of fixed dose rate (FDR) gemcitabine (C) and capecitabine (G) has been demonstrated to be well tolerated in patients with advanced cancers. To determine the activity and safety of this combination in metastatic metastatic biliary tract cancer patients, a phase II trial was conducted. Methods: Patients with unresectable BTC who had pathologically confirmed adenocarcinoma, no prior chemotherapy, ECOG PS &lt; 2 and measurable disease were enrolled. Treatment consisted of FDR G at 800 mg/m(2) infused in 80 minutes on days 1 and 8 every 21 days with C administered orally bid in equal doses (650 mg/m 2 bid) for 14 days (28 doses). Results: Between Feb 2005 and Sept 2008, 30 pts were enrolled. Median age was 67 (45–86) with 14 males. 30 pts were evaluable for response and toxicity. A total of 219 cycles were administered (median, 8; range, 2–16). One patient achieved CR and 8 pts achieved PR giving an overall response rate of 30.0% in intention-to-treat population (95% CI, 19.2–42.6%). And 11 pts (36.6%) had stable disease. The median time to progression of all patients was 7.4 months (mo) (95% CI, 3.2–19.5). The median overall survival was 15.3 mo (95% CI, 4.6–27.9). Grade 3/4 neutropenia and thrombocytopenia were noted in 13.3% and 6.6% of the pts, respectively. Grade 2/3 non-hematologic toxicities were asthenia (50.0 % of pts), diarrhea (16.6%), stomatitis (23.3%) and hand-foot syndrome (6.6%). There was no treatment-related death. Gemcitabine was skipped at least once/reduced in 20%/15% of the patients, respectively. Capecitabine was skipped at least once/reduced in 20%/25% of the patients, respectively. Conclusions: The combination of FDR gemcitabine and capecitabine in this three week cycle is safe and seems to have advantages in activity over other regimens in advanced biliary cancer. No significant financial relationships to disclose.
ENDOTHELIAL MATURATION AND FUNCTION FOLLOWING IMPLANTATION OF ABLUMINAL COATING BIODEGRADABLE POLYMER BASED SIROLIMUS-ELUTING METALLIC STENT VERSUS CONFORMAL COATING DURABLE POLYMER BASED EVEROLIMUS ELUTING STENT
Authors: Hiroyoshi Mori, Qi Cheng, Christoph Lutter, Eduardo Acampado, Liang Guo, Matthew Kutyna, Sho Torii, Emanuel Harari, Renu Virmani, Aloke Finn
Journal: Journal of the American College of Cardiology (2017)
The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment
Authors: Lorenzo Melchor, Alexander Murison, Eileen M Boyle, Christopher P Wardell, John Jones, Martin F Kaiser, Charlotte Pawlyn, David C Johnson, Dil Begum, Paula Proszek, Nasrin Dahir, David A Cairns, Walter Gregory, Roger G Owen, Gordon Cook, Mark T Drayson, Graham H Jackson, Faith E Davies, Brian A Walker, Gareth J. Morgan
Journal: Blood (2014)
ASSOCIATION OF RIGHT ATRIAL FUNCTION WITH INCIDENT ATRIAL FIBRILLATION: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
Authors: Eric Xie, Ricky Yu, Bharath Ambale Venkatesh, Hooman Bakhshi, Susan Heckbert, Elsayed Soliman, David Bluemke, Steven Kawut, Saman Nazarian, Joao Lima
Journal: Journal of the American College of Cardiology (2017)
Final results from NSABP protocol R-04: Neoadjuvant chemoradiation (RT) comparing continuous infusion (CIV) 5-FU with capecitabine (Cape) with or without oxaliplatin (Ox) in patients with stage II and III rectal cancer.
Authors: Carmen Joseph Allegra, Greg Yothers, Michael J. O'Connell, Mark S. Roh, Samia H. Lopa, Nicholas J. Petrelli, Robert W. Beart, Saima Sharif, Norman Wolmark
Journal: Journal of Clinical Oncology (2014)

3603 Background: The two primary aims of NSABP R-04 were 1) Can the oral fluoropyrimidine, Cape be substituted for the standard of care in the curative setting of Stage II & III rectal cancer namely, CIV 5-FU, during neoadjuvant RT; and 2) Can the addition of Ox enhance the activity of fluoropyrimidine sensitized RT? Methods: Pts with clinical stage II or III rectal cancer undergoing preoperative RT (4,500cGy in 25 fractions over 5 wks + boost of 540cGy-1080cGy in 3-6 daily fractions) were randomly assigned to one of four chemotherapy regimens in a 2x2 design: CVI 5-FU (225mg/m2 5 days/wk), with or without intravenous Ox (50mg/m2 /wk x 5) or oral Cape (825 mg/m2 BID 5 days/wk), with or without Ox (50mg/m2/wk x 5). The primary endpoint was local-regional (L-R) tumor control that included L-R tumor recurrence, less than a complete surgical resection, and no surgery for any reason. Results: From July 2004 to August 2010, 1,608 patients were randomly assigned and 99.2% were eligible for analysis. There were no significant differences in 3 year L-R tumor event rates (11.2 vs 11.8%), 5 year DFS (66.4 vs 67.7%), or 5 year OS (79.9 vs 80.8%) between regimens using 5-FU vs Cape; and, 11.2 vs 12.1%, 69.2 vs 64.2%, and 81.3 vs 79.0% for Ox vs no Ox for the three endpoints of L-R events, DFS, and OS. The addition of Ox was associated with significantly more overall and grade 3-4 diarrhea (p<0.0001). Three-year rates of L-R recurrence among all pts who underwent R0 resection ranged from 2.9 – 4.6%. An unplanned subset analysis did not show significant differences for the use of Ox regardless of T-stage or ypCR status. Conclusions: CVI 5-FU or oral Cape combined with RT produced similar outcomes for L-R control, DFS and OS, and establishes Cape as a standard of care in the pre-op rectal setting. Ox did not improve L-R failure rate, DFS, or OS for any patient risk group but did add significant toxicity. Molecular studies using this fully annotated tissue bank are on-going. Support: U10-CA-12027, U10-CA-37377, U10-CA-69651, U-10-CA-69974; Sanofi; Roche. Clinical trial information: NCT00058474.
EFFECTIVENESS AND SAFETY OF APIXABAN, DABIGATRAN, AND RIVAROXABAN COMPARED TO WARFARIN AMONG NON-VALVULAR ATRIAL FIBRILLATION PATIENTS IN THE US MEDICARE POPULATION
Authors: Alpesh Amin, Allison Keshishian, Jeffrey Trocio, Hannah Le, Oluwaseyi Dina, Qisu Zhang, Onur Baser, Lien Vo
Journal: Journal of the American College of Cardiology (2017)
Luminal A and Luminal B subtypes in patients with breast cancer 65 years of age and older.
Authors: Robert Konigsberg, Georg Pfeiler, Nicole Hammerschmid, Tatjana Klement, Christian Dittrich
Journal: Journal of Clinical Oncology (2013)

549 Background: In 2011, the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer (bc) suggested the distinction between Luminal A and Luminal B subtypes. In Luminal A patients (pts) endocrine therapy seems to be sufficiently effective, whereas in Luminal B pts the additional application of chemotherapy should be considered. It is currently unknown, whether the risk stratification into Luminal A and B is comparably or more discriminatory than the established pathologic tumor size (pT) and lymph node (pN) status in pts ≥ 65 years. This analysis evaluates the discriminatory capacity of the new distinction between Luminal A and B and the established prognostic factors in bc pts ≥ 65 years treated with endocrine therapy only. Methods: Clinico-pathological data of 190 bc pts ≥ 65 years diagnosed between 1998 and 2004 were retrospectively analyzed. Pts were classified as Luminal A [ER (+) and/ or PR (+) and Her/2neu (-) and Ki-67 &lt; 14%] or Luminal B [ER (+) and/ or PR (+) and Her2 (-) and Ki-67 ≥ 14%]. The Kaplan-Meier method was used to assess the progression-free survival (PFS) and overall survival (OS) estimates. Differences in survival between groups were tested for significance by the log-rank test. Results: Median age was 74 years (65–92 years) and median time of follow-up was 69 months (0–134 months). 68.9% and 31.1% pts had Luminal A and B subtypes, respectively. 73.3% and 26.7% of pts had pT1 and pT2 tumors, respectively. 79.7% and 20.3% of pts had pN0 and pN1 status, respectively. Overall, median PFS was 33 months. No significant difference regarding PFS could be detected between Luminal A and B pts, between pT1 and pT2 tumors and between pN0 and pN1 status (p=0.458; 0.172; 0.156), respectively. Overall, median OS was not reached. No significant difference regarding OS could be detected between Luminal A and B pts, between pT1 and pT2 tumors and between pN0 and pN1 status (p=0.328; 0.951; 0.976), respectively. Conclusions: In bc pts ≥ 65 years treated with endocrine therapy only, neither the recently consented dichotomization into Luminal A and B subtypes nor pathologic tumor size and lymph node status could be confirmed to be discriminative as propagated in the 2011 St. Gallen Consensus for the overall bc population.
Survival outcome of veterans with myelodysplastic syndrome (MDS) treated with statins.
Authors: Kanza S Abbas, Ang Li, Gustavo Rivero, Nicholas Mitsiades, Sarvari Yellapragada
Journal: Journal of Clinical Oncology (2012)

e17018 Background: Recent studies have shown promising risk modifying effects of statin in various hematologic and solid tumors, such as its ability to induce apoptosis in acute myeloid leukemia cells in-vitro. The impact of statin on MDS treatment outcome has not been evaluated. In this retrospective study, we have examined the overall survival (OS) in veteran MDS patients (pts) with and without exposure to statin with the initial hypothesis that it may impact OS. Methods: After IRB approval, data was collected from Michael E DeBakey VAMC Cancer Registry from January 2000 to October 2011. Pts were included if they had morphological evidence of MDS at the time of diagnosis. Statin exposure was defined as concurrent statin use for at least 6 months prior to and at the time of diagnosis. The primary end-point was OS before and after adjustment with MDS Co-morbidity Index (MDS-CI). Prism 5 was used for statistical analysis. Results: 104 pts with MDS were identified with baseline characteristics depicted in the table. OS of pts exposed to statin was significantly longer when compared with pts not exposed to statin (950d vs 419d, p&lt;0.05). This improvement was especially prominent in pts with higher comorbidities (MDS-CI score&gt;2) (1062d vs 219d, p&lt;0.05) and specifically in those with higher cardiac comorbidities. OS in pts with lower MDS-CI scores was higher in patients on statin but there was no statistical significance (901d vs 663d, p=0.57). Conclusions: In this retrospective study, concurrent statin exposure significantly improved OS in pts with MDS. This improvement, however, was statistically significant in pts with higher overall and cardiovascular co-morbidities. These findings suggest a limited direct anti-tumor benefit of statin in MDS, although the results may have been influenced by the sample size and retrospective design. Prospective studies after stratification by IPSS and MDS-CI are needed to further evaluate the risk-modifying effects of statin in MDS. [Table: see text]
A RED CELL PRESERVATION STRATEGY REDUCES POSTOPERATIVE TRANSFUSIONS IN PEDIATRIC HEART SURGERY PATIENTS
Authors: Meena Nathan, Brielle Tishler, Kimberlee Gauvreau, Gregory S. Matte, Robert J. Howe, Linda Durham, Sharon Boyle, Derek Mathieu, Francis Fynn-Thompson, James Dinardo, Juan Ibla
Journal: Journal of the American College of Cardiology (2017)
SHORT- AND LONG-TERM CAUSE OF DEATH FOLLOWING CORONARY ARTERY BYPASS GRAFTING IN A COHORT OF 33,980 PATIENTS: A NATIONWIDE STUDY
Authors: Jawad Haider Butt, Lars Køber, Peter Skov Olsen, Caroline Bäck, Christian Torp-Pedersen, Rikke Sørensen, Emil Fosbøl
Journal: Journal of the American College of Cardiology (2017)
IMPACT OF ELECTRONIC HEALTH RECORDS ON THE QUALITY OF OUTPATIENT CARDIOVASCULAR CARE DELIVERY IN INDIA: INSIGHTS FROM THE AMERICAN COLLEGE OF CARDIOLOGY'S PINNACLE INDIA QUALITY IMPROVEMENT PROGRAM (PIQIP)
Authors: Ankur Kalra, Jessica Wei, Deepak Bhatt, Karen Anderson, Stefan Rykowski, Prafulla G. Kerkar, Ganesh Kumar, Thomas Maddox, William Oetgen, Salim Virani
Journal: Journal of the American College of Cardiology (2017)
Brief intravenous infusions of oblimersen (Genasense; Bcl-2 antisense) alone and in combination with multiple agents are highly effective in human tumor xenografts
Authors: B. D. Brown, G. D. Paine-Murietta, T. N. Julian, R. P. Warrell
Journal: Journal of Clinical Oncology (2007)

14061 Background: Oblimersen (OBL; Genasense®) is a phosphorothioate-modified antisense oligodeoxynucleotide (ODN) that down-regulates Bcl-2 and may enhance the response to chemotherapy in patients with melanoma and chronic lymphocytic leukemia (CLL). Extensive safety data for Genasense and other systemically administered ODNs have been obtained using low-dose continuous intravenous infusions (CIVI). However, this method is inconvenient and unsuitable for drug combinations that employ frequent or discontinuous dosing. We have now established that OBL can be effectively administered by high-dose, short IV infusions. Methods: We tested multiple treatment schedules of OBL, alone and in combination with paclitaxel, paclitaxel albumin nanoparticles, imatinib, sorafenib, sunitinib, and erlotinib against human tumor xenografts (melanoma A375, NSCLC A549 and H460, colon HT29 and SW620) grown in C.B-17/SCID mice. Results: Periodic OBL monotherapy (high dose IV Q2–3d) yielded consistently superior antitumor efficacy when compared with low- dose daily IV injections. These results have been obtained against all tumor models evaluated to date. This increased efficacy was also observed when OBL was combined with any other therapeutic agent. For combination treatments that included taxanes, efficacy was shown to be schedule dependent. Conclusions: These results, and recent clinical observations, suggest that brief high-dose IV infusions of OBL may significantly increase antitumor activity, and may obviate the need for CIVI. Brief high-dose IV infusions are being incorporated into ongoing clinical trials to evaluate the safety and efficacy of OBL in combination with other agents. No significant financial relationships to disclose.
A prospective study to evaluate the Vulnerable Elders Survey-13 (VES-13) as a tool to identify frail older cancer patients (pts).
Authors: Laura Biganzoli, Leonardo Tenori, Elena Zafarana, Dimitri Becheri, Chiara Biagioni, Silvia Cappadona, Antonella Brunello, Andrea Luciani, Natalie Heather Turner, Giuseppina Sanna, Samantha Di Donato, Claudio Luchinat, Angelo Di Leo, Luca Boni, Giuseppe Mottino
Journal: Journal of Clinical Oncology (2014)

9546 Background: A major challenge in the care of older cancer pts is identification of who might benefit from adjuvant chemotherapy (CT). Frail pts (FP) typically tolerate CT poorly and/or die from causes other than cancer. It is crucial to identify FP to spare them toxicities of potentially non beneficial and non cost-effective therapy. Fried Frailty Criteria (FFC), based on the Cardiovascular Health Study (CHS) tool, and Balducci Frailty Criteria (BFC), based on several components of a comprehensive geriatric assessment (CGA), are the two most commonly used measures to identify FP. Recently a VES-13 score of ≥7 has been suggested as a means to identify FP. Methods: Early-stage cancer pts aged ≥ 70 years who were candidates for adjuvant therapy were classified as frail/ not frail at baseline based on CHS assessment, CGA and VES-13 score. As FP are at risk of disability and death, pts were seen 6-monthly to assess for functional decline (FD), defined as either a change from no impaired activities of daily living (ADL) or instrumental ADL (IADL) to any IADL or ADL impairment, or a decrease of ≥2 or ≥1 in IADL or ADL score, respectively, confirmed at two consecutive reviews. Date and cause of death were also captured. To avoid cancer itself confounding the ability of the evaluated tools to identify FP, the main analysis included only tumor-independent events; that is, events occurring in pts without cancer recurrence. A baseline blood sample was taken to assess if analysis of serum metabolomic spectra could identify a metabolic “frailty” signature. Results: 185 pts, median age 77 years (range 70-91), were enrolled. Most pts had breast (65%) or colorectal cancer (30%). Median follow-up was 36 months. The incidence of tumor-independent events in relation to frailty according to VES-13, BFC and FFC and accuracy of each tool are reported in the table. Conclusions: VES-13 score ≥7 may more accurately identify older patients at risk of health deterioration than FFC or BFC. Data comparing metabolomics with other tools to identify FP will be presented. Tool Criteria used to define FP FP Events Overall accuracy (95% CI) n % n % CHS FFC 31 17 15 48 65% (58% - 72%) CGA BFC 47 25 18 38 70% (63% - 77%) VES-13 Score ≥7 47 25 27 57 75% (68% - 81%)
CIRCULATING MICRORNA PATTERNS ARE ASSOCIATED WITH POST-ABLATION RECURRENCE OF ATRIAL FIBRILLATION
Authors: Oxana Galenko, Madisyn Taylor, Johnny Trang, Stacey Knight, Victoria Jacobs, Michael J. Cutler, Joseph B. Muhlestein, John Carlquist, Kirk Knowlton, T. Jared Bunch
Journal: Journal of the American College of Cardiology (2017)
Abbreviated Treatment with Short-Course Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Is Highly Effective in AIDS-Related Lymphoma (ARL).
Authors: Kieron Dunleavy, Richard Little, Juan Gea-Banacloche, Nicole Grant, Seth Steinberg, Robert Yarchoan, Stefania Pittaluga, Elaine Jaffe, John Janik, Wyndham H. Wilson
Journal: Blood (2004)
TIME-TRENDS IN ANTITHROMBOTIC MANAGEMENT OF PATIENTS WITH AF/FLUTTER TREATED WITH CORONARY STENTS: AN INTERNATIONAL MULTICENTER RESTROSPECTIVE ANALYSIS
Authors: Brian J. Potter, Ricardo Ladeiras-Lopes, Giuseppe Ando’, Giovanni Cimmino, Zied Frikah, Xinyue Chen, Joao Goncalves-Almeida, Vittorio Virga, A. John Camm, Keith Fox
Journal: Journal of the American College of Cardiology (2017)
NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth
Authors: Liang Chen, Justin E Wilson, Mark J Koenigsknecht, Wei-Chun Chou, Stephanie A Montgomery, Agnieszka D Truax, W June Brickey, Christopher D Packey, Nitsan Maharshak, Glenn K Matsushima, Scott E Plevy, Vincent B Young, R Balfour Sartor, Jenny P-Y Ting
Journal: Nature Immunology (2017)
Treatment tolerance and patient-reported outcomes favor online hemodiafiltration compared to high-flux hemodialysis in the elderly
Authors: Marion Morena, Audrey Jaussent, Lotfi Chalabi, Hélène Leray-Moragues, Leila Chenine, Alain Debure, Damien Thibaudin, Lynda Azzouz, Laure Patrier, Francois Maurice, Philippe Nicoud, Claude Durand, Bruno Seigneuric, Anne-Marie Dupuy, Marie-Christine Picot, Jean-Paul Cristol, Bernard Canaud, Aida Afiani, Didier Aguilera, Yamina Azymah, Lynda Azzouz, Francois Babinet, Claire Belloc, Jean- Christophe Bendini, Christian Broyet, Philippe Brunet, Bernard Canaud, Marie-Hélène Chabannier, Lotfi Chalabi, Leïla Chenine, Sylvie Chiron, Jean-Philippe Coindre, Angélique Colin, François Combarnous, Stéphanie Coupel, Alain Cremault, Jean-Paul Cristol, Irima Dancea, Alain Debure, Catherine Delcroix, Pascale Depraetre, Assia Djema, Francis Ducret, Claude Durand, Ibrahim Farah, Dominique Fleury, Abdallah Guerraoui, Marie-Paule Guillodo, Atman Haddj-Elmrabet, Maxime Hoffmann, Richard Ibos, Mohamed Shariful Islam, Dominique Jaubert, Audrey Jaussent, Josiane Joule, Véronique Joyeux, Kristian Kunz, Mélodie Lagarrigue, Achour Laradi, Frédéric Lavainne, Dominique Le Grignou, Gaétan Lebrun, Anne Lefebvre, Jean-Jacques Lefevre, Gaëlle Lefrancois, Vincent Lemaitre, Hélène Leray-Moragues, Mehadji Maaz, Eric Magnant, François Maurice, Hesham Mohey, Marion Morena, Philippe Nicoud, Michel Normand, Hilaire Nzeyimana, Messaoud Ouziala, Sophie Parahy, Laure Patrier, Franck Perrin, Marie-Christine Picot, Philippe Pointet, Jacky Potier, Olivier Puyoo, Isabelle Rey, Jean-Pierre Rivory, Fabienne Rouleau, Bruno Seigneuric, Marie-Odile Serveaux, Danièle Simonin, Angelo Testa, Damien Thibaudin, Cécile Turc-Baron, Carlos Vela, Sandor Vido, Laurence Vrigneaud
Journal: Kidney International (2017)
The Treatment of Delayed Rejection after Boosting of Mononuclear Cells of Her Mother and Chronic Graft Versus Host Disease in Leukemia Recipient Who Underwent Allogeneic Hyplo-Identical Transplantation in Second Remission with Therapeutic Plasma Exchange.
Authors: Zhisheng Jiang, Da Li, Shunjie Wu, Kun Liu, Ying Kang, Gi Chen, Xinghao Lan, Suiquan Chen, Wei Yi
Journal: Blood (2006)
Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)
Authors: Elias Jabbour, Hagop M Kantarjian, Michele Baccarani, Philipp D. le Coutre, Ariful Haque, Neil J. Gallagher, Jorge Cortes, Francis Giles
Journal: Blood (2008)